Chapter 15 Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands

https://doi.org/10.1016/S0079-6123(02)39017-4Get rights and content

Abstract

The involvement of vasopressin (AVP) in several pathological states has been reported recently and the selective blockade of the different AVP receptors could offer new clinical perspectives. During the past few years, various selective, orally active AVP V1a (OPC-21268, SR49059 (Relcovaptan)), V2 (OPC-31260, OPC-41061 (Tolvaptan), VPA-985 (Lixivaptan), SR121463, VP-343, FR-161282) and mixed V1aV2 (YM-087 (Conivaptan), JTV-605, CL-385004) receptor antagonists have been intensively studied in various animal models and have reached, Phase IIb clinical trials for some of them. For many years now, our laboratory has focused on the identification of nonpeptide vasopressin antagonists with suitable oral bioavailability. Using random screening on small molecule libraries, followed by rational SAR and modelization, we identified a chemical series of 1-phenylsulfonylindolines which first yielded SR49059, a V1a receptor antagonist prototype. This compound displayed high affinity for animal and human V1a receptors and antagonized various V1a AVP-induced effects in vitro and in vivo (intracellular [Ca2+] increase, platelet aggregation, vascular smooth muscle cell proliferation, hypertension and coronary vasospasm). We and others have used this compound to study the role of AVP in various animal models. Recent findings from clinical trials show a potential interest for SR49059 in the treatment of dysmenorrhea and in Raynaud's disease. Structural modifications and simplifications performed in the SR49059 chemical series yielded highly specific V2 receptor antagonists (N-arylsulfonyl-oxindoles), amongst them SRI 21463 which possesses powerful oral aquaretic properties in various animal species and in man. SR121463 is well-tolerated and dose-dependently increases urine output and decreases urine osmolality. It induces free water-excretion without affecting electrolyte balance in contrast to classical diuretics (e.g. furosemide and hydrochlorothiazide). Notably, in cirrhotic rats with ascites and impaired renal function, a 10-day oral treatment with SR121463 (0.5 mg/kg) totally corrected hyponatremia and restored normal urine excretion. This compound also displayed interesting new properties in a rabbit model of ocular hypertension, decreasing intraocular pressure after single or repeated instillation. Thus, V2 receptor blockade could be of interest in several water-retaining diseases such as the syndrome of inappropriate antidiuretic hormone secretion (SIADH), liver cirrhosis and congestive heart failure and deserves to be widely explored. Finally, further chemical developments in the oxindole family have led to the first specific and orally active Vib receptor antagonists (with SSR149415 as a representative), an awaited class of drugs with expected therapeutic interest mainly in ACTH-secreting tumors and various emotional diseases such as stress-related disorders, anxiety and depression. However, from the recently described tissue localization for this receptor, we could also speculate on other unexpected uses. In conclusion, the development of AVP receptor antagonists is a field of intensive pharmacological and clinical investigation. Selective and orally active compounds are now available to give new insight into the pathophysiological role of AVP and to provide promising drugs.

References (51)

  • T. Bossmar et al.

    Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions

    Br. J. Obstet. Gynaecol.

    (1997)
  • R. Brouard et al.

    Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea

    Br. J. Obstet. Gynaecol.

    (2000)
  • M.A. Burnatowska-Hledin et al.

    Expression cloning of an AVP-activated, calcium-mobilizing receptor from rabbit kidney medulla

    Am. J. Physiol.

    (1995)
  • M. Burnatowska-Hledin et al.

    VACM-1, a cullin gene family member, regulates cellular signaling

    Am. J. Physiol. Cell Physiol.

    (2000)
  • L.M. Burrell et al.

    Vascular responses to vasopressin antagonists in man and rat

    Clin. Sci. (Colch.)

    (1994)
  • S. Derick et al.

    Characterization of potent new vasopressin analogs to study vasopressin V1b receptors

    J. Pept. Sci.

    (2000)
  • J.J. Dreifuss et al.

    Vasopressin receptor localization and neuronal responsiveness in the rat brain

  • R.M. Freidringer et al.

    Small molecule ligands for oxytocin and vasopressin receptors

    Med. Res. Rev.

    (1997)
  • H. Gavras

    Role of vasopressin in clinical hypertension and congestive cardiac failure: interaction with the sympathetic nervous system

    Clin. Chem.

    (1991)
  • G.E. Gillies et al.

    Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin

    Nature

    (1982)
  • S.R. Goldsmith et al.

    Alpha 2-adrenergic stimulation and vasopressin in congestive heart failure

    J. Cardiovasc. Pharmacol.

    (1989)
  • E. Grazzini et al.

    Molecular and functional characterization of V1b vasopressin receptor in rat adrenal medulla

    Endocrinology

    (1996)
  • D. Hayoz et al.

    Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon

    Rheumatology

    (2000)
  • A. Hurbin et al.

    Expression of the genes encoding the vasopressinactivated calcium-mobilizing receptor and the dual angiotensin II/vasopressin receptor in the rat central nervous system

    J. Neuroendocrinol.

    (2000)
  • S. Jard

    Vasopressin receptors

  • Cited by (102)

    • Efficacy and safety of TS-121, a novel vasopressin V<inf>1B</inf> receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study

      2020, Journal of Psychiatric Research
      Citation Excerpt :

      AVP concentrations in plasma (van Londen et al., 1997) and in the paraventricular nucleus of the hypothalamus in postmortem studies (Purba et al., 1996) are elevated in a subgroup of patients with MDD, compared to healthy controls, raising the hypothesis that excess AVP contributes to HPA axis dysfunction in depression. AVP exerts its effects through three vasopressin receptor subtypes (V1A, V1B and V2 receptors) and the oxytocin receptor (Serradeil-Le Gal et al., 2002a). Among them, the V1B receptor, which is abundantly expressed in the anterior pituitary, mediates the regulation of HPA axis activity by AVP (Saito et al., 1995).

    • Diabetes exacerbates brain pathology following a focal blast brain injury: New role of a multimodal drug cerebrolysin and nanomedicine

      2020, Progress in Brain Research
      Citation Excerpt :

      A malfunction in the hormone itself or its receptor causes other pathologies such as nephrogenic diabetes insipidus (Babey et al., 2011; Robinson and Verbalis, 2003; Schoneberg et al., 1998). Three kinds of vasopressin hormone receptors V1a, V1b, and V2 present in the body (Serradeil-Le Gall et al., 2002) regulate water reabsorption in the distal nephron via activating water channel protein called aquaporins (Dibas et al., 1998). After ADH production in hypothalamic neurons of the supraoptic and paraventricular nuclei, the hormone transported and released into the bloodstream from the posterior pituitary gland (Brownstein et al., 1980; Landgraf and Ludwig, 1991).

    • Translational Medicine Strategies for Drug Development for Impulsive Aggression

      2019, Handbook of Behavioral Neuroscience
      Citation Excerpt :

      For example, certain allosteric modulators of GABAA receptors show a bidirectional relationship with GABA in which case these agents enhance aggression at low doses and reduce aggression at high doses. VASO exerts its physiological and behavioral effects by binding to specific G-protein-coupled receptors (GPCRs) in the central nervous system and certain peripheral tissues/sites (Ring, 2005; Serradeil-Le Gal et al., 2002). Three distinct AVP receptor subtypes have been identified --V1a, V1b, and V2.

    • Renal medulla

      2016, Nephrologie et Therapeutique
    View all citing articles on Scopus
    View full text